12 terminated. 12 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Terminated 12 |
| Phase 1 | 3 | Terminated 3 |
Follow Musculoskeletal Abnormalities: new trials by email Literature Review of Musculoskeletal Abnormalities trials Research Report on Musculoskeletal Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Initiation of Acid Suppression Therapy Prospective Outcomes for Laryngomalacia Famotidine, Speech Language Therapy - Laryngomalacia, Gastro Esophageal Reflux | Phase 1 / Phase 2 | Terminated | Reema Padia | 65 | 2020-11-18 | 2025-07-20 |
| Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma Derazantinib, Derazantinib-paclitaxel-ramucirumab combination - Gastric Adenocarcinoma | Phase 1 / Phase 2 | Terminated | Basilea Pharmaceutica | 47 | 2020-10-06 | 2024-04-04 |
| Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities danicamtiv - Primary Familial Dilated Cardiomyopathy | Phase 2 | Terminated | Bristol-Myers Squibb | 41 | 2020-08-04 | 2025-05-21 |
| Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) Pemigatinib, Pembrolizumab, Gemcitabine - Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma | Phase 2 | Terminated | Incyte Corporation | 7 | 2020-05-14 | 2025-11-04 |
| Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) Pemigatinib - Solid Tumor Malignancy | Phase 2 | Terminated | Incyte Corporation | 111 | 2019-10-17 | 2025-11-04 |
| Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC) Rogaratinib - Squamous-cell Non-small Cell Lung Cancer | Phase 2 | Terminated | Swiss Cancer Institute | 15 | 2019-07-25 | 2022-11-09 |
| Synaptic Plasticity and Cognitive Function in RASopathies Lovastatin, Lamotrigine - Impaired Synaptic Plasticity, Impaired Cognition | Phase 2 | Terminated | Technical University of Munich | 16 | 2019-03-22 | 2023-11-30 |
| Safety and Dosing Study of Glucagon-like Peptide 2 (GLP-2) in Infants and Children With Intestinal Failure Glucagon-Like Peptide 2, Glucagon like peptide-2 - Intestinal Failure, Short Bowel Syndrome | Phase 1 / Phase 2 | Terminated | Alberta Children's Hospital | 13 | 2012-01-01 | 2014-12-23 |
| Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF Brivanib, Irinotecan - Colorectal Cancer, Colorectal Adenocarcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 8 | 2011-08-01 | 2020-09-03 |
| Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome Metyrosine, Placebo - Velo-cardio-facial Syndrome, Psychosis | Phase 2 | Terminated | Bausch Health Americas, Inc. | 2 | 2010-06-01 | 2019-11-22 |
| Evaluating the Use of a Silastic Spring-Loaded Silo for Infants With Gastroschisis Primary placement of a spring-loaded silo, Primary Closure - Gastroschisis | Phase 2 | Terminated | The Hospital for Sick Children | 88 | 2001-06-01 | 2024-06-24 |
| Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome rhIGF-1/rhIGFBP-3 - Noonan Syndrome | Phase 2 | Terminated | Insmed Incorporated | 24 | 2007-03-30 |
Acrocephalosyndactylia (5) · Gastroschisis (2) · Noonan Syndrome (2) · Campomelic Dysplasia (1) · Carcinoma, Transitional Cell (1) · Cardiomyopathy, Dilated (1) · Cognition Disorders (1) · Colorectal Neoplasms (1) · Communication Disorders (1) · DiGeorge Syndrome (1) · Distal Myopathies (1) · Enterocolitis, Necrotizing (1) · Gastroesophageal Reflux (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Infant Nutrition Disorders (1)
Congenital Abnormalities (12) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (12) · Musculoskeletal Diseases (12) · Craniofacial Abnormalities (8) · Bone Diseases (5) · Bone Diseases, Developmental (5) · Craniosynostoses (5) · Dysostoses (5) · Limb Deformities, Congenital (5) · Syndactyly (5) · Synostosis (5) · Cardiovascular Diseases (4) · Digestive System Diseases (4) · Gastrointestinal Diseases (4)
pemigatinib (2) · Carboplatin (1) · Famotidine (1) · Gemcitabine (1) · Glucagon-Like Peptide 2 (1) · Irinotecan (1) · Lamotrigine (1) · Lovastatin (1) · Rogaratinib (1) · Speech Therapy (1) · alpha-Methyltyrosine (1) · brivanib (1) · derazantinib (1) · pembrolizumab (1)
Incyte Corporation (2) · Alberta Children's Hospital (1) · Basilea Pharmaceutica (1) · Bausch Health Americas, Inc. (1) · Bristol-Myers Squibb (1) · Insmed Incorporated (1) · M.D. Anderson Cancer Center (1) · Reema Padia (1) · Swiss Cancer Institute (1) · Technical University of Munich (1) · The Hospital for Sick Children (1)
United States (8) · Germany (5) · Spain (4) · United Kingdom (4) · Canada (3) · France (3) · Italy (3) · Belgium (2) · Japan (2) · Poland (2) · South Korea (2) · Switzerland (2) · Argentina (1) · Australia (1) · Austria (1)
Alfredo Addeo, MD (1) · David Sigalet, MD PhD (1) · Jacob Langer, MD (1) · Kenneth Attie, MD (1) · Luis Feliz Vinas, MD (1) · Michael Overman, MD (1) · Peter Langmuir, MD (1) · Reema Padia, MD (1) · Robert J Shprintzen, PhD (1)
PMID 18926212, PMID 37280688, PMID 38710951, PMID 40762274, PMID 41217321
2019 (2), 2016 (1), 2018 (1)